Chemerin and prediction of diabetes mellitus type 2

Item Type:	Article
Title:	Chemerin and prediction of diabetes mellitus type 2
Creators Name:	Bobbert, T. and Schwarz, F. and Fischer-Rosinsky, A. and Maurer, L. and Moehlig, M. and Pfeiffer, A.F.H. and Mai, K. and Spranger, J.
Abstract:	OBJECTIVE: Insulin resistance and subclinical inflammation are characteristics in the development of type 2 diabetes mellitus (T2DM). The adipokine chemerin has been associated with both factors. The aim of this study was to analyse whether chemerin predicts T2DM. DESIGN: Blood samples of 440 participants of the Metabolic-Syndrome Berlin-Potsdam (MesyBepo) follow-up study without diabetes at baseline were available for chemerin measurement. Mean follow-up of participants was 5.3 years. Glucose metabolism was analysed using oral glucose tolerance test including insulin measurements. Chemerin was measured using a commercially available ELISA. RESULTS: Thirty-five individuals developed T2DM during follow-up. Chemerin predicted incident T2DM (Chemerin 1. Tertile: reference, 2. Tertile: OR 2.33 [0.68-7.95]; Chemerin 3. Tertile: OR 3.42 [1.01-11.58] after adjustment for age, sex, BMI, follow-up time, HbA1c, HOMA-IR and WHR). In a secondary analysis, chemerin also predicted worsening of fasting glucose and HbA1c (adjusted for age, sex, BMI, time of follow-up, WHR, HDL cholesterol and triglycerides). CONCLUSIONS: Our data suggest that chemerin is a weak predictor of T2DM.
Keywords:	Body Mass Index, Chemokines, Follow-Up Studies, Germany, Glucose Tolerance Test, Glycosylated Hemoglobin A, Inflammation, Insulin Resistance, Intercellular Signaling Peptides and Proteins, Predictive Value of Tests, Prognosis, Type 2 Diabetes Mellitus
Source:	Clinical Endocrinology
ISSN:	0300-0664
Publisher:	Wiley-Blackwell
Volume:	82
Number:	6
Page Range:	838-843
Date:	June 2015
Official Publication:	https://doi.org/10.1111/cen.12707
PubMed:	View item in PubMed

Repository Staff Only: item control page